Franco Felizarta
Overview
Explore the profile of Franco Felizarta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1267
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Zeuzem S, Foster G, Wang S, Asatryan A, Gane E, Feld J, et al.
N Engl J Med
. 2018 Jan;
378(4):354-369.
PMID: 29365309
Background: Glecaprevir and pibrentasvir are direct-acting antiviral agents with pangenotypic activity and a high barrier to resistance. We evaluated the efficacy and safety of 8-week and 12-week courses of treatment...
12.
Poordad F, Pol S, Asatryan A, Buti M, Shaw D, Hezode C, et al.
Hepatology
. 2017 Nov;
67(4):1253-1260.
PMID: 29152781
Conclusion: Sixteen weeks of G/P treatment achieved a high SVR12 rate in patients with HCV GT1 infection and past failure to regimens containing either NS5A inhibitors or NS3 protease inhibitors....
13.
Wyles D, Poordad F, Wang S, Alric L, Felizarta F, Kwo P, et al.
Hepatology
. 2017 Sep;
67(2):514-523.
PMID: 28926120
This study assessed the efficacy and safety of ribavirin-free coformulated glecaprevir/pibrentasvir (G/P) in patients with hepatitis C virus genotype 3 infection with prior treatment experience and/or compensated cirrhosis, a patient...
14.
Forns X, Lee S, Valdes J, Lens S, Ghalib R, Aguilar H, et al.
Lancet Infect Dis
. 2017 Aug;
17(10):1062-1068.
PMID: 28818546
Background: The once-daily, ribavirin-free, pangenotypic, direct-acting antiviral regimen, glecaprevir coformulated with pibrentasvir, has shown high rates of sustained virological response in phase 2 and 3 studies. We aimed to assess...
15.
Kwo P, Poordad F, Asatryan A, Wang S, Wyles D, Hassanein T, et al.
J Hepatol
. 2017 Apr;
67(2):263-271.
PMID: 28412293
Background & Aims: Hepatitis C virus (HCV) therapy that is highly efficacious, pangenotypic, with a high barrier to resistance and short treatment duration is desirable. The efficacy and safety of...
16.
Poordad F, Felizarta F, Asatryan A, Sulkowski M, Reindollar R, Landis C, et al.
Hepatology
. 2017 Jan;
66(2):389-397.
PMID: 28128852
Conclusion: The combination of GLE and PIB was highly efficacious and well tolerated in patients with HCV genotype 1 infection and prior failure of DAA-containing therapy; RBV coadministration did not...
17.
Dinges W, Girard P, Podzamczer D, Brockmeyer N, Garcia F, Harrer T, et al.
Medicine (Baltimore)
. 2016 Feb;
95(6):e2673.
PMID: 26871794
The impact of the investigational human immunodeficiency virus type 1 (HIV-1) F4/AS01B vaccine on HIV-1 viral load (VL) was evaluated in antiretroviral therapy (ART)-naive HIV-1 infected adults.This phase IIb, observer-blind...
18.
Lawitz E, Matusow G, DeJesus E, Yoshida E, Felizarta F, Ghalib R, et al.
Hepatology
. 2015 Dec;
64(2):360-9.
PMID: 26704148
Unlabelled: Hepatitis C virus (HCV)-infected patients with cirrhosis are historically a difficult-to-treat population and are at risk of hepatic decompensation. In the phase 2 COSMOS study that evaluated simeprevir (HCV...
19.
Walmsley S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khuong-Josses M, et al.
J Acquir Immune Defic Syndr
. 2015 Aug;
70(5):515-9.
PMID: 26262777
The SINGLE study was a randomized, double-blind, noninferiority study that evaluated the safety and efficacy of 50 mg dolutegravir + abacavir/lamivudine versus efavirenz/tenofovir/emtricitabine in 833 ART-naive HIV-1 + participants. Of...
20.
Lalezari J, Sullivan J, Varunok P, Galen E, Kowdley K, Rustgi V, et al.
J Hepatol
. 2015 Apr;
63(2):364-9.
PMID: 25839406
Background & Aims: Hepatitis C virus (HCV)-infected patients with a history of injection drug use have low rates of initiation and completion of interferon-based therapies. This study evaluated efficacy, safety,...